Chemotherapy for relapsed epithelial ovarian cancer
Por:
Solà I., Roquéi Figuls M., Martí-Carvajal A.J., Ojeda B., Bonfill Cosp X.
Publicada:
1 ene 2013
Resumen:
This is the protocol for a review and there is no abstract. The objectives are as follows: We will assess the clinical effectiveness and safety of second-line chemotherapy for treating women with ovarian cancer sensitive or resistant to a previous course of platinum-based chemotherapy. © 2013 The Cochrane Collaboration.
Filiaciones:
Solà I.:
CIBER Epidemiología y Salud Pública (CIBERESP), Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Antoni Maria Claret 171-Edifici Casa de Convalescència, Barcelona, Catalunya, 08041, Spain
Roquéi Figuls M.:
CIBER Epidemiología y Salud Pública (CIBERESP), Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Antoni Maria Claret 171-Edifici Casa de Convalescència, Barcelona, Catalunya, 08041, Spain
Martí-Carvajal A.J.:
Facultad de Ciencias de la Salud Eugenio Espejo, Universidad Tecnológica Equinoccial, Centro Cochrane Ecuador, Quito, Ecuador
Ojeda B.:
Hospital de la Santa Creu i Sant Pau, Medical Oncology Oncology, Mas Casanovas, 90, Sant Antoni Maria Claret, 167, Barcelona, 08025, Spain
Bonfill Cosp X.:
CIBER Epidemiologia y Salud Pública (CIBERESP), Spain - Universitat Autonoma de Barcelona, Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Antoni M. Claret 171, Casa de Convalescència, Barcelona, Catalonia, 08041, Spain
|